Kathryn Kennedy, MD
Psychiatry · Shreveport, LANPI 1427088020
Payments from drug & device makers
Across 177 payments — averaging $15.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$940
- Teva Pharmaceuticals USA, Inc.$436
- Alkermes, Inc.$336
- Sunovion Pharmaceuticals Inc.$189
- Lundbeck LLC$175
- Otsuka America Pharmaceutical, Inc.$162
- plus $468 from 10 others
What the payments were for
- Food & beverage$2,706100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 72 | $940 |
| Teva Pharmaceuticals USA, Inc. | 28 | $436 |
| Alkermes, Inc. | 19 | $336 |
| Sunovion Pharmaceuticals Inc. | 15 | $189 |
| Lundbeck LLC | 10 | $175 |
| Otsuka America Pharmaceutical, Inc. | 10 | $162 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $141 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $87 |
| Vanda Pharmaceuticals Inc. | 2 | $50 |
| Axsome Therapeutics, Inc. | 2 | $40 |
| Avanir Pharmaceuticals, Inc. | 2 | $40 |
| Corium, LLC | 1 | $30 |
| Indivior Inc. | 1 | $27 |
| Ironshore Pharmaceuticals Inc. | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $15 |
How this compares
$2,706 in reported general payments places this provider in the 75th percentile of 474 psychiatry providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 30 | $10,109 |
| Divalproex Sodium | 111 | $2,537 |
| Aripiprazole | 61 | $1,577 |
| Sertraline Hcl | 168 | $1,387 |
| Fluphenazine Hcl | 12 | $1,175 |
| Trazodone Hcl | 129 | $933 |
| Doxepin Hcl | 64 | $905 |
| Gabapentin | 74 | $903 |
| Donepezil Hcl | 94 | $900 |
| Quetiapine Fumarate | 57 | $892 |
| Memantine Hcl | 43 | $840 |
| Risperidone | 65 | $620 |
| Buspirone Hcl | 33 | $578 |
| Olanzapine | 30 | $496 |
| Losartan Potassium | 39 | $437 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Shreveport
- Guy BrannonShreveport$1.4M
- Gregory BrownShreveport$495K
- Jasjit SinghShreveport$420K
- James BookerShreveport$204K
- Shawn McNeilShreveport$105K
- Matthew MenardShreveport$101K
- Suresh SabbenahalliShreveport$10K
- Christopher BernadasShreveport$6K
- Daniel FeeneyShreveport$5K
- Kashinath YadalamLake Charles$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.